Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775207 | 0.93 | CHRM2 (0.47) | EPHX2CYP2C9CYP2J2GRIN1GRIN2B | |
| SCHEMBL30775277 | 0.85 | GRIN1 (0.53) | EPHX2CYP2C9CYP2J2GRIN1GRIN2B | |
| SCHEMBL2763577 | 0.85 | OPRK1 (0.56) | EPHX2OPRK1HRH3 | |
| SCHEMBL30775253 | 0.84 | AOC3 (0.50) | EPHX2GRIN1GRIN2BOPRK1ALDH1A1 | |
| SCHEMBL2763758 | 0.83 | MEN1 (0.49) | EPHX2HRH3 | |
| SCHEMBL2763241 | 0.83 | SMN1; SMN2 (0.51) | EPHX2GRIN1GRIN2BHRH3ALDH1A1 | |
| SCHEMBL2763728 | 0.80 | MMP13 (0.50) | EPHX2HRH3 | |
| SCHEMBL30775343 | 0.79 | GRIN1 (0.50) | EPHX2GRIN1GRIN2BOPRK1ALDH1A1 | |
| SCHEMBL2637555 | 0.78 | EPHX2 (0.53) | EPHX2CYP2C9CYP2J2NAMPTPARP10 | |
| SCHEMBL30775363 | 0.78 | EPHX2 (0.44) | EPHX2CYP2C9CYP2J2OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | EPHX2 3020/4885CYP2C9 1949/4885CYP2J2 1238/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | EPHX2 3020/4885CYP2C9 1949/4885CYP2J2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.